Global Processing

Hospira Neutropenia Drug Approved in Australia

September 27, 2010
The Associated Press Reports, Hospira has received approval to sell a generic version of the biotech drug Neupogen in Australia. Hospira said its drug, called Nivestim, was approved to prevent febrile neutropenia and to reduce neutropenia caused by chemotherapy. Neutropenia is a lack of white blood cells, and it is a common side effect of chemotherapy treatment. The drugs are intended to help prevent infections. Nivestim is a generic version of Amgen Inc.''s drug Neupogen. Hospira said it plans to start selling the drug in the first half of 2011. Annual sales of Neupogen in Australia total about $24 million, Hospira said.